Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation

Atezolizumab plus bevacizumab therapy has high response rates in patients with advanced hepatocellular carcinoma (HCC). It has been reported that HCC with immune exclusion associated with the signal activation of WNT/β-catenin is resistant to immune checkpoint inhibitors; however, to the best of our...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwano, Akifumi, Yada, Masayoshi, Narutomi, Fumiya, Nagasawa, Shigehiro, Tanaka, Kosuke, Kurosaka, Kazuki, Ohishi, Yoshihiro, Masumoto, Akihide, Motomura, Kenta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178725/
https://www.ncbi.nlm.nih.gov/pubmed/35720502
http://dx.doi.org/10.3892/ol.2022.13337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178725/
https://www.ncbi.nlm.nih.gov/pubmed/35720502
http://dx.doi.org/10.3892/ol.2022.13337

Ejemplares similares